Novo Nordisk to buy RNA technology firm

Denmark's Novo Nordisk, the world's leading insulin maker, said Thursday it will buy US-based Dicerna Pharmaceuticals, a developer of RNA interference technology which targets genes that cause disease.

Diseases, Conditions, Syndromes

Coronavirus damages the endocrine system

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society.

page 1 from 3